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Abstract 
Background: Endometriosis is a gynaecological disorder characterised by the 
presence of endometrial tissue outside the uterine cavity. Apoptosis, regulated by the 
balance of Bcl-2/Bax, plays an important role in the endometrial improvement. 
Metformin, an insulin sensitizer that is known to have beneficial effect in the 
endometriosis treatment, is expected to lower Bcl-2/Bax expression ratio and reduce 
endometrial implants.  
Objective: To explore the effect of metformin on the Bcl-2/Bax expression ratio and 
endometrial implant area of endometriosis-induced mice. 
Methods: This experimental study used 3-month old 33 BALB/c mice of 
endometriosis that were randomly and equally divided into three groups (P0, P1, and 
P2). On the 15th day, the P0 group was first terminated for Bcl-2/Bax examination and 
the size of endometrial implants. The P1 group was given aquabidest, whereas the P2 
group was given metformin 4 mg/day for 14 days. The immunohistochemistry of Bcl-
2/Bax expression were performed from cavum abdomen and pelvis peritoneal tissues 
of the mice and measured by the Remmele Scale Index, whereas the extracted mice’ 
endometrial implants were analysed with computer tracing method. All data normality 
test was calculated with Shapiro-Wilk test. The mean difference test of all groups was 
analysed using the one-way ANOVA test, whereas the mean difference test between 
groups was completed using the Unpaired T-test (LSD/Least Significance Difference). 
Results: The Bcl-2/Bax expression ratio and endometrial implant area in the P2 group 
were significantly lower compared to P0 and P1 (p<0.001). There were no significant 
differences in the Bcl-2/Bax expression ratio or endometrial implant area in P0 and P1 
(p>0.05). 
Conclusion: Metformin may be a potential effective drug treatment for endometriosis 
by decreasing Bcl-2/Bax expression ratio and endometrial implants. 
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INTRODUCTION 
 Endometriosis is a gynaecological condition 
identified with endometrial-like tissue lesions on the 
outer side of the uterine cavity, such as stroma and 
endometrial-like glands, and linked with pain on pelvic 
area and infertility.1  
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 This oestrogen-dependent disorder emits proliferative 
properties, signified with the increase of progesterone 
resistance.2 However, it is known that the pathogenesis 
of endometriosis involves apoptosis and angiogenesis. 
Apoptosis has a major role in the development of 
endometriosis, in which decreased rate of apoptosis will 
exacerbate the condition of endometriosis.3 
Endometriosis occurs frequently in women of 
reproductive age, although the etiopathology of this 
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prevalence of endometriosis in reproductive-age women 
is around 10%.1   
 The apoptosis process is regulated by various agents, 
including one of the most important regulators in the 
apoptosis mechanism, B-cell lymphoma 2 (Bcl-2) 
family, which is first discovered as the proto-oncogene 
in B-cell lymphoma. The excessive expression of Bcl-2 
protects lymphocytes from apoptosis and enables 
endometriosis cells to survive in a longer period. Bcl-2 
is expressed in hormone-sensitive tissues, such as 
endometrium, prostate, and breasts. In the other hand, 
Bcl-2 associated X (Bax) has pro-apoptotic ability that 
will further encourage death susceptibility.3 The balance 
between Bcl-2 and Bax is believed to have a major role 
in determining the possibility of apoptosis. The higher 
apoptotic activity rate is always associated with the 
lower Bcl-2/Bax levels ratio. It is assumed that the 
proportion of Bcl-2/Bax is a significant key factor in 









 In general, the options for the management of 
endometriosis include surgery and medical therapy, 
which are intended to lower oestrogen production, cause 
atrophy of the implant endometrial tissues, and stop the 
menstrual cycle. The effectiveness of endometriosis 
therapy is usually measured by its effectiveness in 
suppressing endometriosis growth, overcoming pain, 
and improving infertility conditions. An ideal therapy for 
endometriosis aims to revert the established 
endometriosis lesions without causing side effects that 
are associated with oestrogen deficiency status. Various 
drugs have been used to treat endometriosis, including 
GnRH agonist, GnRH antagonist, progestagen, 
aromatase inhibitor, danazol, gestrinon, selective 
oestrogen receptor modulator (SERM), progesterone 
inhibitors, selective progesterone receptor modulator, 
angiogenesis inhibitors, as well as immunomodulators.7 
Unfortunately, as of now, there is no single drug that can 
completely cure endometriosis. In certain circumstances, 
the unfavourable consequences of consuming the 
aforementioned drugs may force the long-term treatment 
of endometriosis to be stopped. Several studies suggest 
that medical therapy may prevent conception and not be 
beneficial for fertility.8–10 In addition, the recurrence rate 
of the management of endometriosis still reaches 60 
percent.11–13 There is considerable proof to show that the 
efficacy of oestrogen affects and encourages 
endometriosis. Oestrogen is thought to function through 
the MAPK and PI3K/AKT/mTOR pathways, thus, 
increasing the likelihood of targeting the PI3K pathway 
is likely to be a new approach for the treatment of 
endometriosis.14,15 
 Metformin (1,1-dimethylbiguanide hydrochepatic 
lipaseoride) is an oral anti-diabetic drug that has been 
reported to show a positive impact in menstruation cycle, 
hormonal profile, insulin concentration, insulin 
sensitivity, insulin resistance, and androgen 
concentration in patients.16–18 This drug has been 
considered the potential treatment for endometriosis and 
the effectiveness of metformin has been tested in several 
studies through several pathways. Metformin 
successfully decreases inflammation in endometriosis 
patients by reducing pro-inflammatory cytokines and 
growth factors, such as IL-6, IL-8, and VEGF.19 
Metformin is also equipped with anti-tumour effects by 
activating AMP-activated kinase (AMPK) and inhibiting 
rapamycin (MTOR) in mammalian targets, which are the 
transcription-signal-pathway for proliferative activity. 
Thus, metformin is believed to inhibit proliferation.20 
Due to the positive effects of metformin to the signals 
inside the cells, including NF-kB signals and 
PI3K/AKT/mTOR signals, metformin may lower the 
expression of local oestradiol, inhibit the inflammatory 
process, decrease proliferation rates, and simultaneously 
increase cell apoptosis that will lead to ectopic 
endometriosis tissue regression and normal 
regeneration.21,22 Yilmaz et al. and Oner G. et al. reported 
that the administration of metformin in endometriosis-
induced mice caused a significant reduction of 
endometrial implants.23,24 In a study shown by Takahashi 
et al., endometrial cancer cells that were treated with 
metformin exhibited increased ratio of Bax/Bcl-2.25 
However, the effect of metformin on Bcl-2/Bax 
expression ratio and endometrial implants in 
endometriosis models hasn’t been determined in a single 
research. In this study, the efficacy of metformin for 
endometriosis therapy will be assessed from Bcl-2/Bax 
ratio, as well as the size of endometrial implant area in 








MATERIALS AND METHODS 
Ethical Clearance 
 The ethical clearance was obtained through the 
Health Research Ethics Commission of the Faculty of 
Medicine, Universitas Diponegoro and RSUP Dr. 




 The Metformin (Metformin 500 mg, Hexpharm Jaya) 
drug was obtained from a local pharmacy in Surabaya, 
West Java in a pill form. Every 4 mg of the metformin 
pill was crushed and dissolved in aquabidest 0.1 ml prior 
to being given to the mice.  
 
Animal Handling and Research Design 
 This study used 33 BALB/c female mice with body 
weight ranging from 20 to 30 gram (3 months age). 
Animals were housed in rat standard polypropylene 
cages, kept under controlled temperature (25±2°C), 
humidity (40-60%), and 12 hours of light and 12 hours of 
dark period. The mice were randomly divided into three 
different groups, each comprising 11 mice. Each group 
of mice was placed in a same cage. The first group (P0) 
represented the control group. The second group (P1) was 
Table 1. Bcl-2 expression of Balb/c mice in all groups 
Group Mean±SD Median (Min-Max) 
P0 8.973±2.1809 9.200 (5.5 - 12.0) 
P1 3.764±2.4188 2.600 (2.0 - 8.5) 
P2 2.773±0.5081 3.000 (2.0 - 3.8) 
 
 
Table 2. Bax expression in Balb/c mice in all groups 
Group Mean±SD Median (Min-Max) 
P0 10.991±2.1993 12.000 (4.6 - 12.0) 
P1 4.682±3.0337 3.000 (2.9 - 12.0) 
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given aquabidest as placebo. The last group (P2) 
received metformin. All 33 mice were healthy and 
successfully observed until the end of the study. The 
experiment was held in the laboratory of the Faculty of 
Veterinary Medicine Airlangga University. The mice 
were also obtained from the same laboratory. 
 To induce immunodeficiency in the mice, the mice 
from all groups were injected intramuscularly with 
cyclosporine-A (Sandimmun, Novartis Indonesia)  10 
mg/kg body weight/day on the first day.26,27 Then the 
mice were given 0.1 ml of injection containing 
endometriosis tissues using 1 ml disposable syringe with 
a 16G-sized needle intraperitoneally. The endometriosis 
tissues were sourced from an endometriosis patient 
through a surgery in Central General Hospital Dr. 
Kariadi Semarang. Prior to be injected to the mice, the 
endometriosis tissues were initially prepared by being 
centrifuged two times at 2500 rpm with phosphate-
buffered saline (PBS), removed from the supernatant, 
and added with penicillin 200 IU/ml and streptomycin 
200 μg/ml. Injection of 17β-oestradiol (Ethinyl 
Estradiol) 0.1 ml containing 66 IU of oestradiol was 
carried out intramuscularly in the mice’ thighs on the 
first and fifth days after the injection of endometriosis 
tissues. On the 15th day, all mice in the P0 group were 
terminated to prove the occurrence of endometriosis in 
mice. The mice were first given ketamine (40 mg/kg 
mouse body weight) and acepromazine (0.75 mg/kg 
mouse body weight) as the anaesthetics prior to be 
sacrificed. Then, all endometrial implants in the 
peritoneal cavity of the mice in the P0 group were taken 
for examination of the area of tissue endometrial 
implants, as well as immunohistochemistry and 
histopathology staining. After completing the 
evaluation, the mice were then buried. This experiment 
was performed by a veterinarian.  
 On the 15th day, the P1 group was given aquabidest 
as the placebo through a food tube every day for 14 days, 
which is equivalent to three oestrus cycles. The P2 group 
received metformin supplementation (4 mg/mouse) via 
a food tube every day for 14 days. After receiving the 
intervention for 14 days, then the examination material 
was acquired on the 29th day of the intervention period. 
 
Histological Preparation 
 The cavum abdomen and pelvis peritoneal tissues of 
the mice were fixed in a 10% buffer formalin solution 
for 24 hours. After going through the process of 
dehydration, clearing, infiltration, and embedding, the 
immunohistochemistry painting procedures were carried 
out. The preparations were carried out with endogenous 
peroxidase block with 0.55% hydrogen peroxide in 
methanol for 20 minutes, then put in the microwave for 
10 minutes in 10 mM citrate buffer, pH 6.0.28 The 
preparation was then placed in PBS, pH 7.4 for five 
minutes that was added with 3% normal horse serum 
(NHS) blocking serum for 20 minutes. The primary 
antibodies and secondary antibodies were added after 
removal the excessive NHS. Subsequently, the 
preparation was washed with PBS, pH 7.4 for two 
minutes. After that, the peroxidase-conjugated 
streptavidin (Pierce, USA) 1/1500 was diluted with NHS 
for 60 minutes. The second washing was done in PBS 
pH 7.4 for two minutes. Then peroxidase solution was 
added 25 mg Diaminobenzidine Tetrahydrochloride 
(Sigma. Cat. No. D5637) in Tris HCl buffer and 50 µg 
30% H2O2 for 15 to 20 minutes. The staining with 
Methyl Green was done after the preparation was washed 
again in PBS pH 7.4 for two minutes. After the 
preparation dried, the specimen was ready for the Bcl-2 
and Bax expression examination.  
 
Bcl-2 and Bax Expression and Endometrial Implant 
Area Examination 
 The Bcl-2 and Bax expression value was obtained by 
immunohistochemistry staining method and measured by 
the Rammele Score Index (Immuno Reactive 
Score/IRS).28 The presence of Bcl-2 and Bax expression 
was identified with brown-coloured chromogen in the 
immunohistochemistry staining. The ratio of Bcl-2/Bax 
expression was acquired by dividing the Bcl-2 expression 
value by the Bax expression value. The measurement of 
the endometrial implant area was done by performing 
scissor incisions to extract the endometrial implants of 
the mice. The image of endometrial implant area was 
made on a millimetre block paper, then the cross-
sectional area of endometrial implant was measured in 
millimetre unit using the computer tracing method with 
the software ‘Image Raster’.26 This was performed by an 
anatomic pathologist expert. 
 
Data Analysis  
 The data normality test held for the Bcl-2/Bax 
expression ratio and endometrial implants was completed 
using the Shapiro-Wilk test. The data distribution of Bcl-
2/Bax ratio expression and the extent of endometrial 
implant variables were stated as normal due to the value 
(p> 0.05).  The mean difference test of all groups was 
analysed using the one-way ANOVA test, whereas the 
mean difference test between groups was completed 
using the unpaired t-test (LSD/Least Significance 
Difference). The differences would be considered 
significant by a p<0.05. 
 
RESULTS 
Placebo and Metformin Effect on Bcl-2/Bax 
Expression Ratio 
 The expression of Bcl-2 and Bax of the mice models 
from each study group can be seen in Figure 1. The 
highest mean Bcl-2 expression value was found in P0 
(8,973±2.1809), followed by P1 (3.764±2.4188) and P2 
(2.773±0.5081). On the other hand, the group with the 
highest mean Bax expression was P0 (10.991±2.1993), 
followed by P2 (6.418±2.239) and P1 (4.682±3.0337). 
Based on the Bcl-2/Bax expression ratio of the 
endometriosis mice models, the lowest ratio was found in 
P2 (0.4645±0.121), followed by P1 (0.8000±0.108) and 
P0 (0.8391±0.196). Determination of the mean 
differences between groups using the T-test (LSD) 
revealed that the mean expression ratio of Bcl-2/Bax in 
group P1 was not significantly different relative to the 
mean expression ratio of Bcl-2/Bax in group P0 (p = 
0.537). However, the mean expression ratio of Bcl-2/Bax 
in the P2 group was significantly lower from the mean 
expression ratio of Bcl-2/Bax in the P0 group (p<0.001) 
and also significantly lower from the average expression 




Journal of Biomedicine and Translational Research, 6 (2) 2020, 53-58 
 
Figure 1. Immunohistochemistry staining of Bcl-2 
Expression (left, P0, P1, dan P2) and Bax Expression (right, 
P0, P1, and P2). The arrow marks show the Bcl-2 and Bax 
expression on the mice endometrial tissue, characterised by 














Mean Area of Endometrial Implants 
 The highest mean endometrial implant area of 
endometriosis-induced mice was found in P0 
(137.9355±50.82254 mm), followed by P1 
(112.4445±48.1336 mm) and P2 (23.3527±22.27861 
mm). The subsequent analysis to determine the mean 
difference between the implant area between groups 
using the t-test (LSD) showed that the mean area of 
endometrial implants in the P1 group did not have any 
significant difference from the mean area of endometrial 
implants in the P0 group (p=0.169). The mean area of 
endometrial implants in the P2 group was significantly 
lower relative to the mean area of endometrial implants 
in the P0 group (p<0.001) and also statistically lower 
compared to the mean area of endometrial implants in 
the P1 group (p<0.001) (Table 4). 
 
DISCUSSION 
 Endometriosis is a condition where ectopic 
endometrial cells show abnormal proliferation and 
apoptosis rate. Apoptosis has a major function in the 
maintenance of tissue homeostasis and the elimination 
of excessive or dysfunctional cells. A study reported that 
normal endometrial cells of healthy women that are 
removed during menstruation will not continue to live 
outside of the ectopic location due to the programmed 
cell death.29 Meanwhile, a lowered apoptosis rate may 
enhance the ectopic survival and implantation of these 
cells, which eventually boost endometriosis abnormal 
growth. The increased expression levels of anti-apoptotic 
factors and decreased pro-apoptotic factors have been 
linked to the incapability of endometrial cells to send out 
















 The balance of Bcl-2/Bax expression has a vital role 
in the process of cell death, in which a low value of the 
ratio will induce apoptosis. The application of the Bcl-
2/Bax expression ratio is more useful for apoptosis 
determination compared to the expression of Bcl-2 or 
Bax individually due to the strong association between 
the high apoptotic activity and the low level of Bcl-2/Bax 
expression ratio.6 Based on the results of the present 
study, the administration of metformin in endometriosis 
mice (P2) reduced the balance of Bcl-2/Bax expression 
twice higher compared to the group that was given 
aquabidest (P1) and the control group mice (P0). It can 
be assumed that the administration of metformin can 
increase apoptosis in endometriosis mice, characterised 




Figure 2. Comparison of Bcl-2/Bax expression ratio of Balb/c 
endometriosis mice model 
 
 The findings of the present research are consistent 
with the previous research conducted by Oner et al. and 
Tian et al. in mice with endometriosis models, in which 
the administration of metformin showed an improvement 
Table 3. Mean difference test of Bcl-2/Bax expression ratio in 
all groups 
Group N Mean±SD P value* 
P0 11 0.8391 ± 0.196 < 0.001 
P1 11 0.8000 ± 0.108  
P2 11 0.4645 ± 0.121  
*One-way Anova test  
*The result of comparison between groups with 
LSD test. 
P0 vs P1: p=0.537; P0 vs P2: p=0.001; P1 vs P2: 
p=0.001 
 
Table 4. Mean difference test of endometrial implant  
area in all groups 
Group N Mean±SD P value* 
P0 11 137.9355 ± 50.82254 < 0.001 
P1 11 112.4445 ± 48.1336  
P2 11 23.3527 ± 22.27861  
*One-way Anova test 
*The result of comparison between groups with 
 LSD test. 
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of endometriosis and even a reduction in the size of 
endometrial implants.24,30 Metformin can induce the 
death of the cells in eutopic endometrium by reducing 
the expression of Bcl-2 protein and increasing 
expression of p53 and Bax.22 The effect of metformin on 
the endometrial implants is assumed to be caused by the 
action of metformin on AMPK and inhibits 
prostaglandin and inflammatory reactions. Metformin 
can lower the activity of aromatase enzyme and improve 
the hyperandrogenic environment by increasing the 
content of sex hormone-binding globulin (SHBG), thus 
the content of oestradiol in the circulation and 
endometrium is lowered.24 
  
 
Figure 3. Comparison of endometrial implant area of Balb/c 
endometriosis mice model 
 
 Metformin decreases the stimulated StAR expression 
by PGE2 by preventing the translocation of cAMP 
response binding element protein (CREB)-regulated 
transcription coactivator 2 (CRTC2) which is generally 
induced by PGE2. Metformin performs this action by 
increasing AMPK phosphorylation, thus, the CREB-
CRTC2 complex will not be formed. StAR plays a major 
role in the process of steroidogenesis by providing 
continuous cholesterol supply for oestradiol production. 
StAR stimulates cholesterol entry into mitochondria 
where cholesterol is converted to pregnenolone, then to 
androstenedione, oestrone, and finally to oestradiol. As 
a result of the administration of metformin, the capacity 
of stromal cells that convert androstenedione to oestrone, 
which depends on aromatase activity, is decreased. DNA 
synthesis, as a marker of proliferation, also decreases. It 
is believed that metformin may regulate and activate 
AMPK, which then inhibits the mTOR pathway through 
TSC2 protein.31–33  
 The limitations of this research were to assess data 
(Bcl-2/Bax expression ratio and endometrial implants) 
before the intervention was carried out in the control 
group (P0), where the value was considered the same for 
the pre-intervention data in the P1 group and P2 group. 
This has happened because to obtain pre-intervention 
data, the mice must be terminated and their peritoneum 
must be taken to measure the endometrial implants and 
sample preparation for the immunohistochemical 
examination to assess Bcl-2/Bax expression ratio. 
Additionally, the mice’ insulin resistance status was also 
not tested. 
CONCLUSION 
 This study demonstrated that metformin 
administration on mice with endometriosis, positively 
improved the Bcl-2/Bax expression ratio which suggests 
a higher rate of apoptosis compared to the group that was 
given placebo. Furthermore, the mice group that was 
given metformin also reported a reduction in the size of 
the endometrial implants, possibly through the 
metformin activity on the AMPK, hence, inhibiting 
prostaglandin, inflammatory reactions, and mTOR 
pathway. In conclusion, the result of the present study 
shows the potential of metformin to be developed as the 
treatment for endometriosis patients and may prompt 
future research on this particular field. 
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